Bacteriophage encapsulation: Trends and potential applications

Choińska-Pulit, Anna; Mituła, Paweł; Śliwka, Paulina; Łaba, Wojciech; Skaradzińska, Aneta

doi:10.1016/j.tifs.2015.07.001

Cited by 75 publications

(44 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, encapsulation can overcome other problems related to the application of bacteriophages in food industry processes. The materials used in bacteriophage encapsulation have been examined in several studies1213 and include alginate, alone or in combination with other materials810161718. However, few studies have described the in vivo use of alginate-encapsulated bacteriophages212227.…”

Section: Discussionmentioning

confidence: 99%

“…These problems can be successfully addressed by encapsulation, which would be able to protect bacteriophages under similar potentially deleterious conditions. Among the many diverse biomaterials used for phage encapsulation are cellulose, liposomes, alginate, whey proteins, and gelatin, which have been applied using different techniques1213. Alginate is one of the most common biomaterials used in microencapsulation, including that of probiotics1415 and, as recently shown, bacteriophages.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Microencapsulation with alginate/CaCO3: A strategy for improved phage therapy

Colom

Cano‐Sarabia

Otero

et al. 2017

Sci Rep

120

View full text Add to dashboard Cite

Bacteriophages are promising therapeutic agents that can be applied to different stages of the commercial food chain. In this sense, bacteriophages can be orally administered to farm animals to protect them against intestinal pathogens. However, the low pH of the stomach, the activities of bile and intestinal tract enzymes limit the efficacy of the phages. This study demonstrates the utility of an alginate/CaCO3 encapsulation method suitable for bacteriophages with different morphologies and to yield encapsulation efficacies of ~100%. For the first time, a cocktail of three alginate/CaCO3-encapsulated bacteriophages was administered as oral therapy to commercial broilers infected with Salmonella under farm-like conditions. Encapsulation protects the bacteriophages against their destruction by the gastric juice. Phage release from capsules incubated in simulated intestinal fluid was also demonstrated, whereas encapsulation ensured sufficient intestinal retention of the phages. Moreover, the small size of the capsules (125–150 μm) enables their use in oral therapy and other applications in phage therapy. This study evidenced that a cocktail of the three alginate/CaCO3-encapsulated bacteriophages had a greater and more durable efficacy than a cocktail of the corresponding non-encapsulated phages in as therapy in broilers against Salmonella, one of the most common foodborne pathogen.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Microencapsulation with alginate/CaCO3: A strategy for improved phage therapy

Colom

Cano‐Sarabia

Otero

et al. 2017

Sci Rep

120

View full text Add to dashboard Cite

show abstract

“…Potential reduction in phage titres due to phage inactivation attributed to stomach acidity may in part have been responsible for failure of a recent clinical trial aiming to show reduction in acute bacterial diarrhoea symptoms in children using phage therapy [14]. This is primarily due to the acidic conditions encountered in the stomach, and the presence of bile and digestive enzymes and other proteases in the intestinal tract and stomach [30–32]. Therefore, there is a clear need to protect phages against these adverse gastrointestinal conditions by encapsulating them [31–33], and to control their targeted release at the site of infection e.g.…”

Section: Introductionmentioning

confidence: 99%

Microencapsulation of Clostridium difficile specific bacteriophages using microfluidic glass capillary devices for colon delivery using pH triggered release

et al. 2017

View full text Add to dashboard Cite

The prevalence of pathogenic bacteria acquiring multidrug antibiotic resistance is a global health threat to mankind. This has motivated a renewed interest in developing alternatives to conventional antibiotics including bacteriophages (viruses) as therapeutic agents. The bacterium Clostridium difficile causes colon infection and is particularly difficult to treat with existing antibiotics; phage therapy may offer a viable alternative. The punitive environment within the gastrointestinal tract can inactivate orally delivered phages. C. difficile specific bacteriophage, myovirus CDKM9 was encapsulated in a pH responsive polymer (Eudragit® S100 with and without alginate) using a flow focussing glass microcapillary device. Highly monodispersed core-shell microparticles containing phages trapped within the particle core were produced by in situ polymer curing using 4-aminobenzoic acid dissolved in the oil phase. The size of the generated microparticles could be precisely controlled in the range 80 μm to 160 μm through design of the microfluidic device geometry and by varying flow rates of the dispersed and continuous phase. In contrast to free ‘naked’ phages, those encapsulated within the microparticles could withstand a 3 h exposure to simulated gastric fluid at pH 2 and then underwent a subsequent pH triggered burst release at pH 7. The significance of our research is in demonstrating that C. difficile specific phage can be formulated and encapsulated in highly uniform pH responsive microparticles using a microfluidic system. The microparticles were shown to afford significant protection to the encapsulated phage upon prolonged exposure to an acid solution mimicking the human stomach environment. Phage encapsulation and subsequent release kinetics revealed that the microparticles prepared using Eudragit® S100 formulations possess pH responsive characteristics with phage release triggered in an intestinal pH range suitable for therapeutic purposes. The results reported here provide proof-of-concept data supporting the suitability of our approach for colon targeted delivery of phages for therapeutic purposes.

show abstract

“…These losses can occur during passage through the gastrointestinal tract, during industrial processes and others, which can minimize the antimicrobial effect of bacteriophages. The encapsulation also permits the controlled liberation of viral particles under the influence of specific conditions [8].…”

Section: Introductionmentioning

confidence: 99%

Evaluation of microencapsulation of the UFV-AREG1 bacteriophage in alginate-Ca microcapsules using microfluidic devices

Boggione

Batalha

Gontijo

et al. 2017

Colloids and Surfaces B: Biointerfaces

View full text Add to dashboard Cite

A B S TR A C TThe indiscriminate use of antibiotics and the emergence of resistant microorganisms have become a major challenge for the food industry. The purpose of this work was to microencapsulate the bacteriophage UFV-AREG1 in a calcium alginate matrix using microfluidic devices and to study the viability and efficiency of retention. The microcapsules were added to gel of propylene glycol for use as an antimicrobial in the food industry. The technique showed the number of the phage encapsulation, yielding drops with an average 100-250 µm of diameter, 82.1 ± 2% retention efficiency and stability in the gel matrix for 21 days. The gel added to the microencapsulated phage showed efficiency (not detectable on the surface) in reducing bacterial contamination on the surface at a similar level to antimicrobial chemicals (alcohol 70%). Therefore, it was possible to microencapsulate bacteriophages in alginate-Ca and apply the microcapsules in gels for use as sanitizers in the food industry.

show abstract

Bacteriophage encapsulation: Trends and potential applications

Cited by 75 publications

References 60 publications

Microencapsulation with alginate/CaCO3: A strategy for improved phage therapy

Microencapsulation with alginate/CaCO3: A strategy for improved phage therapy

Microencapsulation of Clostridium difficile specific bacteriophages using microfluidic glass capillary devices for colon delivery using pH triggered release

Evaluation of microencapsulation of the UFV-AREG1 bacteriophage in alginate-Ca microcapsules using microfluidic devices

Contact Info

Product

Resources

About